PGRMC1在三阴性乳腺癌中的表达及其与ki-67的相关性

Expression of PGRMC1 in triple negative breast cancer and its correlation with ki-67

目的 探讨PGRMC1与三阴性乳腺癌（TNBC）分期、分级等各临床病理指标的相关性,建立患者随访系统,并分析其与肿瘤增殖性抗原ki-67的相关性。方法 利用免疫组化检测90例TNBC患者组织中PGRMC1和ki-67的表达,应用χ^2检验,用Kaplan-Meier方法分析PGRMC1表达与生存情况,Log-rank检验比较生存率,用相关性分析和ROC曲线探索其内在相关性。结果 90例TNBC组织中PGRMC1呈现高表达50例。PGRMC1的表达与肿瘤的体积、ki-67的表达、淋巴结转移和临床分期相关（P〈0.05）;TNBC组织中PGRMC1与年龄和肿瘤病理分级无关（P〉0.05）。TNBC组织中PGRMC1的表达与患者的总生存率（Log-rank=15.614,P=0.0001）和无瘤生存率（Logrank=14.371,P=0.031）密切相关。结论 TNBC组织中PGRMC1的表达水平与肿瘤转移、临床分期以及ki-67的增殖呈正相关,多因素分析结果提示PGRMC1可作为TNBC的潜在肿瘤生物标志物以及癌干细胞的治疗靶标。

Objective To explore the correlation between PGRMC1 and TNBC staging and grading and other clinicopathological indicators, establish a patient follow-up system, and analyze its correlation with tumor proliferating antigen ki-67. Methods The expression of PGRMC1 and ki-67 in 90 cases of TNBC was detected by immunohistochemistry.The Kaplan-Meier method was used to analyze the expression and survival of PGRMC1 by χ^2test. Log-rank test was used to compare the survival rate, and the relativity analysis and ROC curve were used to explore the intrinsic correlation.Results In 90 cases of TNBC tissues, PGRMC1 was expressed highly in 50 cases. The expression of PGRMC1 was closely related to tumor volume, ki-67 expression, lymph node metastasis and clinical staging（P〈0.05）; there was no correlation between PGRMC1 and age and tumor pathological grade in TNBC tissues（ P〉0. 05）. The expression of PGRMC1 in TNBC tissues was closely related to the tumor-free survival rate（Log-rank=14.371, P=0.031） and overall survival rate（Log-rank=15.614, P=0.0001）. Conclusion The expression level of PGRMC1 in TNBC tissues is positively correlated with tumor metastasis, clinical staging and proliferation of ki-67. Multivariate analysis indicates that PGRMC1 can be a potential tumor biomarker for TNBC and a therapeutic target for cancer stem cells.